Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.
About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...
Swiss drugmaker Roche began a study last year of its experimental drug, RG6237, as a monotherapy in people with high body ...
About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...
About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...
Doctors say drugs that improve muscle mass could benefit older or infirm people at greater risk of falls and fractures ...
Discover Veru Inc.'s latest Q1 2025 updates on enobosarm & sabizabulin trials, financials, & strategic pivots in cardiometabolic and inflammation treatment.
Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...
Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting ...
Detailed price information for Veru Inc (VERU-Q) from The Globe and Mail including charting and trades.
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial of its experimental drug CagriSema — a combination of semaglutide and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results